APO-CILAZAPRIL 2.5 MG
CILAZAPRIL (CILAZAPRIL MONOHYDRATE) : 2.5 MG · DIN 02291142 · APOTEX INC
Health Canada status: MARKETED
What is APO-CILAZAPRIL?
APO-CILAZAPRIL 2.5 MG contains CILAZAPRIL (CILAZAPRIL MONOHYDRATE) : 2.5 MG. It is listed in the Health Canada Drug Product Database under DIN 02291142, held by APOTEX INC, supplied as TABLET for ORAL administration. Health Canada currently lists it as marketed, status dated 01-Feb-2007. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
What is APO-CILAZAPRIL used for?
Treatment of mild to moderate essential hypertension and congestive heart failure (as adjunctive therapy with digitalis and/or diuretics).
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
Product details and regulatory record
| DIN | 02291142 |
|---|---|
| Brand name | APO-CILAZAPRIL |
| Generic / active ingredient | CILAZAPRIL (CILAZAPRIL MONOHYDRATE) : 2.5 MG |
| Manufacturer | APOTEX INC |
| Strength | 2.5 MG |
| Dosage form | TABLET |
| Route of administration | ORAL |
| Schedule | Prescription |
| ATC code | C09AA08 CILAZAPRIL |
| AHFS class | 24:32.04 |
| Biosimilar | No |
| Health Canada status | MARKETED |
| Status date | 01-Feb-2007 |
| Original market date | 2007-02-01 00:00:00 |
How is it administered?
Hypertension: Normally used after diuretics/beta-blockers fail. CHF: Adjunctive therapy with digitalis/diuretics. Start with low dose under medical supervision, especially in at-risk patients.
Included because it drives pack selection and wastage. Consult the monograph.
How is it stored and handled?
Not explicitly detailed in provided text (refers to Storage and Stability section).
How is it supplied?
Not explicitly detailed in provided text (refers to Dosage Forms, Composition and Packaging section).
Contraindications
Hypersensitivity to cilazapril or ACE inhibitors; history of angioedema; anuria; ascites; pregnancy; nursing women; concomitant use with aliskiren (in diabetes/renal impairment) or neprilysin inhibitors.
Warnings and precautions
Risk of angioedema (can be fatal), severe hypotension (especially first dose), neutropenia/agranulocytosis, and hyperkalemia. Use caution in aortic stenosis or hypertrophic cardiomyopathy.
What can be used instead?
Other Canadian products sharing ATC code C09AA08 CILAZAPRIL. 6 of 33 DINs in this group are currently marketed — marketed products are listed first, because that is what can actually be bought. These tables describe supply, not clinical equivalence: substitution rests with the prescriber or pharmacist, and interchangeability is determined provincially.
| Product | Strength | Form | Manufacturer | Health Canada status | DIN |
|---|---|---|---|---|---|
| APO-CILAZAPRIL | 5 MG | TABLET | APOTEX INC | MARKETED | DIN 02291150 |
| INHIBACE | 5 MG | TABLET | CHEPLAPHARM ARZNEIMITTEL GMBH | MARKETED | DIN 01911481 |
| MYLAN-CILAZAPRIL | 1 MG | TABLET | MYLAN PHARMACEUTICALS ULC | MARKETED | DIN 02283778 |
| MYLAN-CILAZAPRIL | 2.5 MG | TABLET | MYLAN PHARMACEUTICALS ULC | MARKETED | DIN 02283786 |
| MYLAN-CILAZAPRIL | 5.0 MG | TABLET | MYLAN PHARMACEUTICALS ULC | MARKETED | DIN 02283794 |
| APO-CILAZAPRIL | 1 MG | TABLET | APOTEX INC | DORMANT | DIN 02291134 |
| CILAZAPRIL | 1 MG | TABLET | SANIS HEALTH INC | CANCELLED POST MARKET | DIN 02350963 |
| CILAZAPRIL | 1.0 MG | TABLET | COBALT PHARMACEUTICALS COMPANY | CANCELLED PRE MARKET | DIN 02345218 |
| CILAZAPRIL | 2.5 MG | TABLET | COBALT PHARMACEUTICALS COMPANY | CANCELLED PRE MARKET | DIN 02345226 |
| CILAZAPRIL | 2.5 MG | TABLET | SANIS HEALTH INC | CANCELLED POST MARKET | DIN 02350971 |
Who else supplies CILAZAPRIL worldwide?
Nexara tracks national medicine registries and published price lists across multiple markets. CILAZAPRIL appears in 16 registered pack listings across 7 markets, published on 5 different national price bases. Where a Canadian route is closed, that is where an alternative route of supply starts — subject to the import rules in both countries.
Registered listings are not stock. Ask us to confirm what can actually be sourced for your order.
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.